Tenax Therapeutics Q2 2024 Adj EPS $(1.83) Beats $(1.99) Estimate
Portfolio Pulse from Benzinga Newsdesk
Tenax Therapeutics (NASDAQ:TENX) reported a Q2 2024 adjusted EPS of $(1.83), beating the analyst consensus estimate of $(1.99) by 8.04%.
August 13, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tenax Therapeutics reported a Q2 2024 adjusted EPS of $(1.83), which is better than the analyst consensus estimate of $(1.99). This positive earnings surprise may boost investor confidence in the short term.
The better-than-expected EPS indicates that Tenax Therapeutics is performing better than analysts anticipated, which is likely to have a positive impact on the stock price in the short term as it may boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100